First, it is known that IL-6 has two signaling pathways, classical signaling and trans-signaling, and we evaluated the effects of trans-signaling of cancers and fibroblasts on tumor immunity by simultaneous administration of IL-6 and IL-6R [61–63] In this study, the effect of IL-6 via classical signaling on cells originally expressing membrane IL-6R, such as B cells or myeloid cells, was not evaluated. The gene discussed is IL6; the disease is neoplasm.